Adipotide

A synthetic chimeric peptidomimetic (~2,611 Da) that destroys white adipose tissue vasculature. Its CKGGRAKDC homing motif binds prohibitin/annexin A2 on WAT blood vessels, while the D(KLAKLAK)₂ domain triggers mitochondrial apoptosis in those endothelial cells. Developed at UT MD Anderson; Phase 1 trial (NCT01262664) terminated with no published results.

Preliminary evidence Unregulated Metabolic

Written by WhatPeptide Editorial Team · Last updated 2026-03-18

Half-life

Not formally characterized; rapid clearance consistent with small peptide therapeutics

Dosage range

Primates: 0.10-0.75 mg/kg/day SC; optimal 0.43 mg/kg/day (Barnhart et al., PMID 22072637). Human Phase 1 starting dose: 0.03 mg/kg SC daily × 28 days (NCT01262664)

Administration

Subcutaneous injection

Research level

Preliminary

How Adipotide works

The CKGGRAKDC motif selectively binds the prohibitin/annexin A2 receptor complex on endothelial cells of white adipose tissue vasculature. Upon internalization, the D(KLAKLAK)₂ proapoptotic domain disrupts mitochondrial membranes, triggering endothelial apoptosis, adipose tissue ischemia, and fat cell death. In primates, caused 38.7% body fat reduction in 4 weeks.

Also known as: FTPP, Fat-Targeted Proapoptotic Peptide, Prohibitin-TP01

Research relevance

Fat Loss

Moderate relevance 75

Side effects & safety

Renal proximal tubule injury (dose-dependent, reversible) Elevated serum creatinine and BUN Single-cell tubular necrosis at high doses (0.75 mg/kg) Dehydration risk secondary to renal effects

Contraindications

Pre-existing renal impairment (primary toxicity target is kidney)

Dehydration

Pregnancy

Consult a healthcare provider before use if any of these apply to you.

FAQ

What is Adipotide? +

What is Adipotide researched for? +

Adipotide has the strongest research relevance for Fat Loss. Evidence is based on preliminary or early-stage research.

What are the side effects of Adipotide? +

Reported side effects include Renal proximal tubule injury (dose-dependent, reversible), Elevated serum creatinine and BUN, Single-cell tubular necrosis at high doses (0.75 mg/kg), Dehydration risk secondary to renal effects. Key contraindications: Pre-existing renal impairment (primary toxicity target is kidney); Dehydration; Pregnancy.

Is Adipotide FDA approved? +

Adipotide is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.

How is Adipotide administered? +

Adipotide is typically administered via subcutaneous route. Researched dosage range: Primates: 0.10-0.75 mg/kg/day SC; optimal 0.43 mg/kg/day (Barnhart et al., PMID 22072637). Human Phase 1 starting dose: 0.03 mg/kg SC daily × 28 days (NCT01262664). Half-life: Not formally characterized; rapid clearance consistent with small peptide therapeutics.

Explore similar peptides

5-Amino-1MQ

Preliminary evidence

Metabolic

5-Amino-1MQ is a small-molecule NNMT inhibitor studied in preclinical obesity and metabolic syndrome models for its ability to reduce fat mass and improve metabolic parameters. It has shown promise in rodent studies for promoting leanness without apparent toxicity at research doses.

NAD+

Moderate evidence

Metabolic

NAD+ is a critical coenzyme present in all living cells, central to cellular energy metabolism, DNA repair, and sirtuin-mediated longevity pathways. Circulating and intracellular NAD+ levels decline with age, and parenteral supplementation is studied for reversing age-related metabolic decline and improving mitochondrial function.

Tesofensine

Moderate evidence

Metabolic

A triple monoamine reuptake inhibitor (SERT IC₅₀ 11 nM, NET 1.7 nM, DAT 65 nM) of the phenyltropane family, originally developed by NeuroSearch for neurodegeneration. Acquired by Saniona (2014), sublicensed to Medix for Mexico/Argentina (2016). Phase 2: 0.5 mg achieved 9.2% placebo-subtracted weight loss (Astrup et al., Lancet 2008). Viking Phase 3 (372 patients, 24 weeks) completed Dec 2018. COFEPRIS favorable opinion Feb 2023 but approval withheld Nov 2024.